Exjade (Novartis Pharmaceuticals Corporation)


Welcome to the PulseAid listing for the Exjade drug offered from Novartis Pharmaceuticals Corporation. This Iron Chelating Activity [MoA],Iron Chelator [EPC],Cytochrome P450 3A4 Inducers [MoA],Cytochrome P450 2C8 Inhibitors [MoA],Cytochrome P450 1A2 Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view the details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Novartis Pharmaceuticals Corporation
NON-PROPRIETARY NAME: deferasirox
SUBSTANCE NAME: DEFERASIROX
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Iron Chelating Activity [MoA],Iron Chelator [EPC],Cytochrome P450 3A4 Inducers [MoA],Cytochrome P450 2C8 Inhibitors [MoA],Cytochrome P450 1A2 Inhibitors [MoA]
ROUTE: ORAL
DOSAGE FORM: TABLET, FOR SUSPENSION
MARKETING CATEGORY NAME: NDA
START MARKETING DATE: 2005-11-30
END MARKETING DATE: 0000-00-00


Exjade HUMAN PRESCRIPTION DRUG Details:

Item DescriptionExjade from Novartis Pharmaceuticals Corporation
LABELER NAME: Novartis Pharmaceuticals Corporation
DEA SCHEDULE:
ACTIVE STRENGTH: 125(mg/1)
START MARKETING DATE: 2005-11-30
END MARKETING DATE: 0000-00-00
PRODUCT ID: 0078-0468_dda5d82e-577e-4961-bc92-3adb52509b3c
PRODUCT NDC: 0078-0468
APPLICATION NUMBER: NDA021882

Other DEFERASIROX Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Novartis Pharmaceuticals CorporationExjade